Responses
Regular and Young Investigator Award Abstracts
Immunotherapy Toxicities
1240 Safety profile of pembrolizumab monotherapy versus pembrolizumab with combined treatments: analysis of french pharmacovigilance database
Compose a Response to This Article
Other responses
No responses have been published for this article.
